Group 1: Acquisition and Strategic Moves - Eli Lilly announced the acquisition of Ventyx Biosciences for $1.2 billion, with a premium of 62%, to enhance its NLRP3 inhibitor pipeline, expected to complete in the first half of 2026 [1] - Bangyao Biotech appointed Xiang Yu as CEO starting January 1, 2026, who brings 17 years of experience in the pharmaceutical and healthcare sectors, aiming to accelerate the commercialization of CGT pipelines [2] Group 2: Market Performance and Product Approvals - Jingfeng Medical's stock surged over 30% on its first day of trading in Hong Kong, reflecting strong market confidence in its surgical robot technology and global strategy [3] - Luye Pharma's innovative drug Ruoxinlin received acceptance for a new indication application in China, targeting generalized anxiety disorder, with a clinical efficacy rate exceeding 80% [4] - Hansoh Pharmaceutical's Amivantamab was approved for a new indication in combination with chemotherapy for advanced non-small cell lung cancer patients with specific EGFR mutations, reinforcing its position in the EGFR-TKI market [5]

Group 1 - The Hang Seng Index closed down 0.94%, with the technology sector experiencing the largest decline [1] - The Hang Seng Technology Index fell by 1.81%, with notable drops from BYD Co. Ltd. (-3.93%), Alibaba (-3.25%), and NetEase (-2.88%) [3] - The Hang Seng Bank Index also saw a decline of 1.1%, with Standard Chartered down 2.43% and China Construction Bank down 1.42% [3] Group 2 - The Hang Seng Healthcare Index rose by 2.47%, driven by significant gains from companies like CanSino Biologics (+7.31%) and 3SBio (+7.16%) [3] - Other healthcare stocks such as WuXi Biologics and Innovent Biologics also saw increases of 5.92% and 5.38% respectively [3] - More than ten healthcare stocks recorded gains exceeding 3% [3]

Market Overview - The Hong Kong stock market continued to decline, with the Hang Seng Index closing at 26,149.31 points, down 309.54 points, a decrease of 1.17% [2] - The Hang Seng Tech Index closed at 5,678.34 points, down 60.18 points, a decrease of 1.05% [4] Company Focus: Zhihua Holdings - Zhihua Holdings' controlling shareholder, Chen Zhi, is linked to the recently apprehended founder of the Taizi Group, who is involved in fraud [5] - Zhihua Holdings, listed in 2017, has seen its stock price never exceed HKD 1, peaking at HKD 0.82, and dropping to below HKD 0.10 in 2023, with a low of HKD 0.031 at the end of last year [5] - Following sanctions against Chen Zhi by the US and UK, he resigned from his executive roles in October 2022, and his successor also resigned shortly after [5][9] Stock Performance - Zhihua Holdings experienced a significant stock price increase, with an intraday peak rise of 120% and a closing increase of over 94.29%, bringing its market capitalization to approximately HKD 114 million [6] - Chen Zhi also controls another Hong Kong-listed company, Kun Group, with a 55% stake, which has a market capitalization of about HKD 139 million [11] Sector Performance - Among the Hang Seng Index constituents, New World Development rose over 3%, China Shenhua increased over 2%, and Hansoh Pharmaceutical gained over 1% [12] - Conversely, Lenovo Group fell over 5%, and Tingyi Holdings dropped over 4% [12] - In the Hang Seng Tech Index, Horizon Robotics rose over 3%, Bilibili increased over 2%, while Alibaba fell over 2% and Sunny Optical Technology dropped over 4% [12] Capital Flow - There was a significant net sell-off by southbound funds, exceeding HKD 4.9 billion by the end of the trading day [13] Market Outlook - Analysts from Galaxy Securities expect active trading in the Hong Kong market to continue, predicting an overall upward trend [15] - Everbright Securities also anticipates continued upward movement due to domestic policy support and a weaker US dollar [15] - However, Zheshang International notes that the market's fundamentals remain weak, suggesting a cautious but optimistic approach to the market's short-term outlook [15]

Major Events - GCL-Poly Energy (00451) plans to issue 186.5 million subscription shares to partner with Pharos to accelerate the integration of Web3 and the renewable energy industry [1] - Hansoh Pharmaceutical (03692) receives drug registration certificate from the National Medical Products Administration for the fifth indication of Amelot (Ametinib Mesylate Tablets) [1] - Green Leaf Pharmaceutical (02186) has its application for the new indication of the innovative drug Ruoxinlin for the treatment of generalized anxiety disorder accepted in China [1] - Xianjian Technology (01302) receives formal registration approval from the National Medical Products Administration for the G-iliacTM Pro iliac artery covered stent system [1] - Meirui Health International (02327) plans to acquire 100% equity of Jiangsu Yide for 125 million yuan [1] - Century International (00959) joint venture signs a memorandum of understanding with WPT to jointly develop, operate, and commercialize mobile applications [1] Operating Performance - Fast Retailing (06288) reports first-quarter earnings with a net profit attributable to shareholders of 147.445 billion yen, an increase of 11.7% year-on-year [1] - Agile Group (01813) reports December pre-sale amount of 420 million yuan, a decrease of 56.7% year-on-year [1] - Baolong Real Estate (01238) projects total contract sales of approximately 7.272 billion yuan for 2025, a decrease of 43.13% year-on-year [1] - China General Nuclear Power (01816) expects total on-grid electricity of approximately 2,326.48 billion kilowatt-hours for 2025, an increase of 2.36% year-on-year [1] - Lingbao Gold (03330) issues a profit warning, expecting net profit for the 2025 fiscal year to be approximately 1.503 to 1.573 billion yuan, an increase of about 115% to 125% year-on-year [1]

翰森制药(03692)发布公告，集团创新药阿美乐(甲磺酸阿美替尼片)获中国国家药品监督管理局 ("NMPA")签发的药品注册证书，批准增加"阿美乐联合培美曲塞和铂类化疗药物适用于具有表皮生长因 子受体("EGFR")外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌 ("NSCLC")成人患者的一线治疗"适应症。此为阿美乐获批的第五项适应症。 ...

智通财经APP讯，翰森制药(03692)发布公告，集团创新药阿美乐 (甲磺酸阿美替尼片)获中国国家药品监督管理局("NMPA")签发的药品注册证书， 批准增加"阿美乐联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体("EGFR")外显子19缺失或外显子 21(L858R)置换突变的局部晚期或转 移性非小细胞肺癌("NSCLC")成人患者的一线治疗"适应症。此为阿美乐获批的第五项适应症。 （原标题：翰森制药(03692)：阿美乐® (甲磺酸阿美替尼片)第五项适应症获国家药品监督管理局签发药品注册证书） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願公告 阿美樂® （甲磺酸阿美替尼片）第五項適應症 獲國家藥品監督管理局簽發藥品註冊證書 翰森製藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董 事會」）欣然宣佈，本集團創新藥阿美樂® （甲磺酸阿美替尼片）獲中國國家藥品監 督管理局（「NMPA」）簽發的藥品註冊證書，批准增加「阿美樂®聯合培美曲塞和 鉑類化療藥物適用於具有表皮生長因子受體（「EGFR」）外顯子19缺失或外顯子 21(L858R)置換突變的局部晚期或轉移性非小細胞肺癌（「NSCLC」）成人患者的一 線治療」適應症。此為阿美樂®獲批的第五項適應症。 關於阿美樂® 阿美樂® （甲磺酸阿美替尼片）是中國首個原研三代EGFR-TKI創新藥，此前已於 中國獲批四項適應症，分別為：二零二零年獲批用於既往經EGFR-TKI治療進 展，且T790M突變陽性的局部晚期或轉移性NSCLC患者；二零二一年獲批用於 具有EGFR外顯子19 ...

Group 1: Financial Performance - In the first three quarters of 2025, the company achieved an operating income of 318 million yuan, a decrease of 14.52% compared to the same period last year [2] - The net profit attributable to shareholders was 24.6 million yuan, down 2.38% year-on-year [3] - In Q3, the net profit attributable to shareholders increased by 61.24% year-on-year, and the non-recurring net profit grew by 107.84% [3] Group 2: Business Development - The company focuses on two main sectors: micro-special motors and precision drug delivery devices [3] - In the micro-special motors sector, the company is enhancing its market presence by deepening relationships with existing clients and actively seeking new customers [3] - In the precision drug delivery device sector, the company is strengthening cooperation with strategic clients and has multiple customized projects in the testing and validation stages [4] Group 3: Industry Position - The company has established itself as a significant player in the micro-special motors and components industry, with a stable market share and notable clients such as Midea, Gree, and Haier [4] - In the precision drug delivery device market, the company is a leading domestic manufacturer, serving major pharmaceutical companies and adapting its products for various drug delivery needs [4] Group 4: Future Growth Strategy - The company aims to enhance operational efficiency and profitability while seeking synergistic acquisition targets to achieve technological upgrades and market expansion [6] - The growth model is based on a dual-driven strategy focusing on micro-special motors and healthcare, with an emphasis on consolidating existing business and expanding into new applications [6] - The strategic blueprint includes deepening the market presence in micro-special motors and medical devices while exploring new applications in smart homes, automotive, and robotics [6]

Core Viewpoint - The Hong Kong stock market's biopharmaceutical sector is experiencing a long-awaited uptrend, prompting YK Pharmaceutical to accelerate its plans for a dual primary listing in Hong Kong despite facing significant operational challenges and declining financial performance [1][3]. Financial Performance - YK Pharmaceutical's revenue has been on a downward trend, decreasing from 45.21 billion in 2022 to 37.67 billion in 2024, with a significant drop of 39.4% to 13.04 billion in the first seven months of 2025 [9]. - The company's net profit has also declined sharply from 3.39 billion in 2022 to 1.21 billion in 2024, with a net loss of 1.46 billion reported in the first seven months of 2025 [9]. - Gross margin has decreased from 63.5% in 2022 to 45.7% in 2025, indicating a continuous weakening of profitability [9]. Business Transformation - YK Pharmaceutical is transitioning from a leader in generic drugs to focusing on innovative drug development, with a pipeline that includes 11 oligonucleotide drugs, 2 mRNA vaccines, and 3 innovative traditional Chinese medicines [5][6]. - The company aims to avoid traditional competition in the innovative drug space by leveraging a dual-track approach of self-research and authorized introduction [5]. Cash Flow and Dividend Controversy - The company's cash and cash equivalents fell to 875 million by the end of July 2025, a 30% decrease from the end of 2024, with negative net cash flow from operating activities recorded at -27.32 million [11]. - Despite declining performance, YK Pharmaceutical distributed over 8.9 billion in dividends from 2022 to 2024, including a substantial 4.95 billion in 2023, raising concerns about the sustainability of such payouts during a critical transformation phase [12]. IPO and Market Conditions - The upcoming IPO in Hong Kong is primarily aimed at raising funds for innovative drug research, production facility construction, and operational capital, addressing the company's current financial pressures [13]. - The favorable market conditions in 2025, including the recovery of the Hong Kong biopharmaceutical sector and improved investor sentiment towards quality biopharmaceutical companies, provide a strategic window for the listing [13][14]. Risks and Challenges - The company faces significant risks, including stringent valuation expectations from Hong Kong investors, the early-stage nature of its innovative pipeline, and potential challenges in achieving commercial success [15]. - The dual listing may also lead to valuation discrepancies between the A-share and Hong Kong markets, posing additional risks to the company's financial stability [15]. Industry Perspective - YK Pharmaceutical's journey reflects the broader trend of Chinese generic drug companies needing to innovate and invest in R&D to remain competitive amid industry shifts towards centralized procurement and innovation-driven growth [16].

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 1.17% to close at 26,149.31 points, and a total trading volume of 268.275 billion HKD [1] - The Hang Seng Tech Index dropped by 1.05%, while the Hang Seng China Enterprises Index decreased by 1.09% [1] - Everbright Securities noted that domestic policy support and a weaker US dollar may lead to continued fluctuations and potential upward movement in the Hong Kong market [1] Blue-Chip Performance - New World Development (00016) led blue-chip stocks, rising by 3.21% to 102.8 HKD, contributing 7.39 points to the Hang Seng Index [2] - Morgan Stanley predicts a 10% increase in Hong Kong residential property prices this year due to rising demand from mainland buyers and limited supply [2] - Other notable blue-chip movements included China Shenhua (01088) up 2.56% and Huaneng Power (00322) down 4.18% [2] Sector Highlights - Large tech stocks faced pressure, with Alibaba and Tencent both declining [3] - The commercial aerospace sector saw significant gains, with Asia Pacific Satellite rising over 20% [4] - Semiconductor stocks performed well, with Tian Shu Zhi Xin (09903) increasing by 8.44% [3] - The brain-computer interface sector gained traction, with companies like Brainhole Technology (02203) rising by 9.33% [4][6] New Listings and Market Activity - New listings included Zhipu AI (02513), which rose by 13.17% on its debut, marking it as the "first stock of large models" [7] - COSCO Shipping Energy (01138) saw a strong performance, increasing by 7.09% amid rising demand for legal oil tankers due to geopolitical dynamics [8] - Xindong Company (02400) also performed well, rising by 6.46% following the global launch of its mobile game [9] Corporate Actions - HSBC Holdings (00005) faced pressure, declining by 2.28% as it proposed a privatization plan valued at approximately 290.3 billion HKD, with a buyout price of 155 HKD per share, representing a 30.3% premium [10]